Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

ivate Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges, risks and costs inherent in business integrations and in achieving anticipated synergies; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, the providing of estimates of financial measures, in accordance with GAAP and related standards. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in the company's Report on Form 10-Q, for the period ended June 30, 2011, and in its other filings with the SEC. Further, uncertainties or other circumstances, or matters outside of the company's control between the date of this release and the date that its Form 10-Q for the quarter ended September 30, 2011, is filed with the SEC could potentially result in adjustments to reported results. The company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

Mylan Inc. and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited; in thousands, except per share amounts)Three Months Ended September 30,Nine Months End
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... The Mexico Biomedical Sensors market is estimated at $0.20 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... period following the filing of the Company,s Investigational ... U.S. Food and Drug Administration (FDA) has passed ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/30/2015)... England , August 31, 2015 ...   einer Frau   für chirurgische   Behandlung     ... von 7-90   werden für eine   verheerende ... 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen in ... Astellas gab heute bekannt, dass  Action on Fistula ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... MannKind Corporation (Nasdaq: MNKD ) today ... Inc. (NYSE: PFE ) to purchase Pfizer,s ... and assets related to the production of bulk insulin, ... a quantity of bulk insulin and a license to ...
... computational resources the idea of a computational laboratory ... conceptual and technical challenges. Chief among these is ... of incomplete knowledge and information, reflected in observed ... has, in recent years, grown from a collection ...
... a leading medical device/biopharmaceutical company located in Santa Ana, ... CHO-CD XP(TM) Culture System to their cell culture product ... set of chemically-defined*, serum-free, and animal component free media ... and production for recombinant CHO cell lines. It ...
Cached Biology Technology:MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2Irvine Scientific Launches IS CHO-CD XP(TM) 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... a big killer, responsible for more than 35,000 deaths in ... with the deadly H5N1 strain of bird flu are gradually ... scientists are discussing ways to better understand the flu and ... modify flu as a bioweapon to make it even more ...
... Cigarette smoke can turn normal breast cells cancerous by ... development, University of Florida scientists report. , While some ... damaged DNA, many others become unable to access their ... a UF study published today (Aug. 21) in the ...
... here reveals that a new strain of mice offers the ... leukemia and should greatly aid the development of new drugs ... transgenic mouse, develops a malignancy that closely mimics chronic lymphocytic ... hampered the development of new treatments for CLL as well ...
Cached Biology News:Scientists aim to thwart use of flu as bioweapon 2Scientists aim to thwart use of flu as bioweapon 3Cigarette smoke blocks cell repair mechanism, University of Florida study shows 2Cigarette smoke blocks cell repair mechanism, University of Florida study shows 3Mouse mimics chronic leukemia, will aid drug development 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: